HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print October 23, 2006

This Article Full Text Full Text (PDF) All Versions of this Article: jlb.0306196v1 81/1/67    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Urbonaviciute, V. Articles by Voll, R. E. Search for Related Content PubMed PubMed Citation Articles by Urbonaviciute, V. Articles by Voll, R. E.

(Journal of Leukocyte Biology. 2007;81:67-74.)
© 2007 by Society for Leukocyte Biology

Factors masking HMGB1 in human serum and plasma

Vilma Urbonaviciute^*, Barbara G. Fürnrohr^*, Christian Weber^*, Martin Haslbeck, Sabine Wilhelm^*, Martin Herrmann and Reinhard E. Voll^*,,1

^* IZKF Research Group 2, Nikolaus-Fiebiger-Center of Molecular Medicine, University of Erlangen-Nürnberg, Erlangen, Germany;
Department Chemistry, Technical University Munich, Munich, Germany; and
Department of Internal Medicine 3, University Hospital Erlangen, Erlangen, Germany

¹Correspondence: IZKF Research Group 2, Nikolaus-Fiebiger-Center, Glückstrasse 6, 91054 Erlangen, Germany. E-mail: rvoll{at}molmed.uni-erlangen.de

ABSTRACT

High mobility group box 1 protein (HMGB1) is a ubiquitously expressed architectural chromosomal protein. Recently, it has become obvious that HMGB1 can also act as a proinflammatory mediator when actively secreted during cell activation or passively released from necrotic cells. HMGB1 appears to play an important role in the pathogenesis of diseases, including sepsis and rheumatoid arthritis. However, easy, sensitive, and reliable detection systems are required to investigate the clinical significance of HMGB1 in clinical samples for diagnosis and prognosis of diseases. Here, we describe sensitive ELISAs for the detection of HMGB1 in cell culture medium and cell lysates. However, these assays failed to reliably quantitate HMGB1 in serum and plasma when compared with immunoblot analysis. We found that serum/plasma components bind to HMGB1 and interfere with its detection by ELISA systems. In most serum/plasma samples investigated, including those from healthy individuals, we detected IgG antibodies binding to HMGB1. The titers of these antibodies correlated with the capacity of sera to interfere with the detection of recombinant HMGB1 by ELISA. Furthermore, HMGB1 coimmunoprecipitated with several proteins including IgG1, as identified by mass spectrometry. These HMGB1 interacting proteins are currently characterized and may contribute to complex formation, masking, and possibly, modulation of cytokine activity of HMGB1.

Key Words: autoantibodies • ELISA • systemic lupus erythematosus • rheumatoid arthritis

This article has been cited by other articles:

				S. M. Rowe, P. L. Jackson, G. Liu, M. Hardison, A. Livraghi, G. M. Solomon, D. B. McQuaid, B. D. Noerager, A. Gaggar, J. P. Clancy, et al. Potential Role of High-Mobility Group Box 1 in Cystic Fibrosis Airway Disease Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 822 - 831. [Abstract] [Full Text] [PDF]

				L. M. Alleva, A. C. Budd, and I. A. Clark Systemic Release of High Mobility Group Box 1 Protein during Severe Murine Influenza J. Immunol., July 15, 2008; 181(2): 1454 - 1459. [Abstract] [Full Text] [PDF]

				M. E. Bianchi DAMPs, PAMPs and alarmins: all we need to know about danger J. Leukoc. Biol., January 1, 2007; 81(1): 1 - 5. [Abstract] [Full Text] [PDF]